The move to the major bioscience hub brings new access to talent and supports commercialization operations
DURHAM, N.C., Sept. 29, 2022 /PRNewswire-PRWeb/ -- Curie Co, the standard for long-lasting, sustainable personal care, today announced the relocation of their headquarters from New York City to North Carolina's Research Triangle Park (RTP). Along with this move, Curie Co attracted and hired industry veteran, Alan Berry, to serve as their Chief Technology Officer.
Recognizing the Raleigh-Durham area as one of the fastest growing metropolitan areas in the country and a leading bioscience hub, Curie Co relocated its headquarters from the Johnson & Johnson Innovation JLabs in New York City. The move places the company closer to prospective, top-tier talent, and allows it to benefit from the state's friendly business climate as well as RTP's biotechnology and biomanufacturing resources.
With this move, Curie Co plans to expand its cutting-edge enzyme optimization capabilities. Curie fashions personal care solutions from the basic building blocks of life by teaching abundant, naturally-occurring enzymes to perform the same function as legacy preservatives and with efficiency that is orders of magnitude better. These enzymes are fully biodegradable and are gentle for people and the planet.
"Curie Co is a collection of top scientists from Fortune 500 companies around the globe who align under the same belief that sustainability isn't a luxury, it's our obligation," said Erika Milzcek, CEO and founder of Curie Co. "RTP is a hub of bright and ambitious talent and well-established industrial biotechnology infrastructure and resources. This move allows us to grow and scale as a company alongside this amazing community."
The move has already put Curie Co in a strong position to support commercialization and attract top-rate talent, such as the company's new CTO, Alan Berry. Berry's role will be to lead the development of Curie's technology to meet demands across many industrial applications and markets. Berry is an applied microbiologist with over 30 years of experience in the industrial biotechnology and biopharmaceutical industries and an extensive industrial and academic network. Most recently, Berry spent over a decade with Novozymes, heading all research and development related to metabolic engineering and leading the Microbial Development organization.
"I joined Curie Co because the technology our company has developed meets a genuine, unmet need across multiple industries while being both technologically and commercially realistic," said Alan Berry, CTO of Curie Co. "The cutting-edge technology and the outstanding industrial experience and track record of the management team, in combination with the bright, energetic scientists who deliver our results in the lab every day, sets our enzyme products up for resounding success. I'm excited to be a part of the journey."
Berry earned his PhD in Biological Sciences from Binghamton University under the direction of Roy A. Jensen, upon which he was awarded the university's Distinguished Dissertation award. Berry then moved into conducting his postdoctoral research at The University of Illinois Health Sciences Center at Chicago under the direction of Ananda M. Chakrabarty. It was there that he was awarded a National Research Service Award postdoctoral fellowship from the National Institutes of Health, Allergy, and Infectious Diseases. Berry is a contributing author on 40 journal articles and book chapters and is a co-inventor on several issued patents representing eight patent families.
"We are so pleased and honored to have Alan join Curie Co," said Erika Milczek. "He has already spearheaded the identification of the technological demands of our customers. The future of Curie Co is bright and we cannot wait to develop solutions with Alan that serve the people and the planet with the most gentle, sustainable standards."
With Berry's 32 years of R&D experience in industrial biotechnology and biopharmaceutical development, and his extensive industrial and academic network, Curie Co is poised to deliver leading-edge, biobased solutions for the personal care industry.
To learn more about Curie Co and see open positions, please visit: https://www.curieco.com/.
ABOUT CURIE CO
Curie Co is the standard for long-lasting, sustainable personal care. We fashion biological solutions from the basic building blocks of life.
If there is a biological problem, there is a biological solution. To date, personal care has been constrained by legacy petrochemical-based preservatives. As consumer trends, sustainability issues, and regulatory changes mount, formulators are looking for a bio-based upgrade without limitation.
Curie Co's enzyme optimization platform teaches abundant, naturally-occurring enzymes to perform the same function as legacy preservatives and with efficiency that is orders of magnitude better.
Our enzymes are gentle for people and the planet–they are fully biodegradable and catalytic. From hand soap, body wash, hair care products, skincare, and beyond, we give product formulators the freedom to build a powerful, long-lasting product that is nature-based from the bottom up.
Founded in 2017, Curie Co is a collection of top scientists from Fortune 500 companies around the globe. Our interdisciplinary team unites under the belief that sustainability is not a luxury, it's our obligation. Curie Co is proudly based in Research Triangle Park.
To learn more, please visit: https://www.curieco.com/.
Media Contact
Gabrielle Ferguson, Jones-Dilworth, 3092020670, [email protected]
SOURCE Curie Co
Share this article